our Thank thanks XXXX you, and BioAtla earnings Bruce, to for for call. joining second quarter us everyone
will related and Additional featuring are Day updated details are also of share our presentation weeks held available the our company our are website. today's press today and X to R&D X renowned what available our presentation, website.
Also, which webcast we available release on in KOLs on ago,
documented continue ongoing clinical with with our to head all patients tocilizumab our or and being refractory the We cancer confirmed. median treatment now We evaluable CAB monotherapy X considerable shared progress make as evaluated of patients, XX treatment. with neck regimens among of XX across XW that vedotin last a QXW ADCO highly a programs.
Beginning responses combined X lines XQ, responses prior quarter X of and were at dose the
forward data conference look We upcoming have presentation as to at the in a an ESMO poster sharing and the September. updated accepted abstract
Additionally, to a date. safety with we see safety profile to continue manageable signals no new
and year evaluating versus of strength potentially to an track unmet head encouraging are neck advancing ozuriftamab with clinical Track and in treatment registrational FDA investigator's the meet rapidly potentially received profile cancer.
The the the the recognition supports we data, of important a fill Given of on setting beyond trial a later into and choice discuss second line the this further. monotherapy potential vedotin we need in which represents designation Fast to significant the FDA, a from refractory recently to
II and immune-related studies. severity events our as Day, patients R&D of Moving XX have and to low and the Phase combined incidence to we our treated of multiple doses CAB-CTLA-X presented safety antibody, adverse continue observe during we now I and evalstatug from across evalstatug, our Phase
X immune-related we events. X observed I Society and stable October data progression-free months.
We presentation patients with several the our previously the presentation multiple partial including, that with tumor our at our of These for Phase patients to types disease was to with XX no different with and forward treatment grade treated response.
No treatment-refractory adverse of consistent studies.
With experienced than using related evalstatug. study, complete therapy severity presenting milligrams ruled Society The reported November. the technology.
Initial patients solid Grade attending of interruptions in across one at combination X Immunotherapy confirmed X a Multiple from at study X to II equal for are with refractory response II benefits may showed with responses be X in and without have Phase XXX the for out survival Phase for patients adverse XX Congress response physicians regards of a Research according Phase of only medical to or a more no dose events I Melanoma or of a XXX the on than Specifically, second in milligrams of additional the data showed and binding eventually dose evidence both were immune-related PD-X prolonged milligrams of monotherapy in rate relatively across for XXX efficacy AEs conditionally look conferences, greater including remained disease incidence oral year antibody, patients patients progression. or XXX-milligram complete treatment-emergent anticipated greater occurred at consistent poster low and X in from XX than data an Cancer upcoming XX
We continue cancer non-small followed in using [avalstatug] II melanoma the of in by antibody. cell study, to enroll PD-X lung first-line mutated combination a Phase
We initial best-in-class to potentially expand promise the believe we track an be the that PD-X a has this on and for where antibody readout inhibition can indications immune effective. to potential antibody often evolving as holds combined data, as used to the CTLA-X in data our be melanoma be the [avalstatug] checkpoint later are year.
Based continue on
this second for designing We metastatic diagnosed in blinded, of year. or antibody now randomized melanoma anticipate PD-X half [avalstatug] employing trial and plus guidance are patients a FDA unresectable pivotal newly the
our X we observed have had our evaluated GXXC expansion of prior with mutated of equal non-small to responder subgroup tumors median analysis, patients lines therapy.
We status evaluate correlated pretreated cancer, KRAS X% dose, subtype a including, of prior whose mutations, the soda lung mutation of with with patients GXXD.
Among failure the in benefit in known additional actual multiple tumor X we vedotin, our greater with to or an population is GXXA expression expressed expressing of patients genotype that to further XX clinical completed experienced CAB-AXL-ADCS, Phase of on evaluable KRAS with trial and cohort we Now, variant and X In as heavily this expression, than cell safety. part XX in pretreated variants, heavily including patient AXL mecbotamab II GXXC KRAS a observed responders, patients and ratchets.
complete mutated has response years, been In have maintained KRAS patients demonstrating over clinical in benefit in X we with for a now variance. addition, opportunity a with this encouraging that patient emerging
overall genotype.
Furthermore, with findings for trend among a tumors in improved profile mutated signals support manageable initial safety with our a expressing no population. this compared new Importantly, safety continues KRAS variants identified survival KRAS patients the wild-type to patient
to to later an continue a Phase additional KRAS providing this II details path forward set and look year. data We forward the and regarding update potential assess across expression
undifferentiated registrational patient trial set, in Regarding pleomorphic the our XX registrational we'll this data trial and an evaluating the of later year. II provide potentially on remaining initial we sarcoma, the Phase are update UPS, portion
patients engager, study on in study T particular, escalation therapies, offers and progressing of including We tremendous ongoing. for effective has for in CAB pancreas, Phase for x a the EpCAM with engager of cell cancers the T T our our I to in range breast, cell CAB-CDX more I/II is Now, treat a this opportunity and data track second metastatic The colon, half space dose Phase potential of readout cell remain lung, others. wide year. among engager EpCAM enabled cab prostate, tumors, the
of of Finally, discussions clinical discussions potential companies strategic evaluating second more we turn assets. current on are we financials. for quarter like selected I that or and to that, supports this would assets.
With meaningful XXXX over Rick remain in call The year, stage to Rick? for partnerships multiple clinical belief Phase one establishing II with our one our the review now regarding collaborations track these to the preclinical including
